title: Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
abstract: RNA splicing plays a fundamental role in human biology. Its relevance in cancer is rapidly emerging as demonstrated by spliceosome mutations that determine the prognosis of patients with hematologic malignancies. We report studies using FD-895 and pladienolide-B in primary leukemia cells derived from patients with chronic lymphocytic leukemia and leukemia-lymphoma cell lines. We found that FD-895 and pladienolide-B induce an early pattern of mRNA intron retention - spliceosome modulation. This process was associated with apoptosis preferentially in cancer cells as compared to normal lymphocytes. The pro-apoptotic activity of these compounds was observed regardless of poor prognostic factors such as Del(17p), TP53 or SF3B1 mutations and was able to overcome the protective effect of culture conditions that resemble the tumor microenvironment. In addition, the activity of these compounds was observed not only in vitro but also in vivo using the A20 lymphoma murine model. Overall, these findings give evidence for the first time that spliceosome modulation is a valid target in chronic lymphocytic leukemia and provide an additional rationale for the development of spliceosome modulators for cancer therapy.
authors: Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
authors: Manoj K
authors: MK
authors: Kashyap
authors: Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
authors: Deepak
authors: D
authors: Kumar
authors: Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.
authors: Reymundo
authors: R
authors: Villa
authors: Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.
authors: James J
authors: JJ
authors: La Clair
authors: Integrative Genomics and Bioinformatics Core, Salk Institute for Biological Studies, La Jolla, CA, USA.
authors: Chris
authors: C
authors: Benner
authors: Center for Computational Biology, Institute for Genomic Medicine, University of California, San Diego, La Jolla, CA, USA.
authors: Roman
authors: R
authors: Sasik
authors: Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
authors: Harrison
authors: H
authors: Jones
authors: Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA.
authors: Emanuela M
authors: EM
authors: Ghia
authors: Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA CLL Research Consortium, and Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
authors: Laura Z
authors: LZ
authors: Rassenti
authors: Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA CLL Research Consortium, and Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
authors: Thomas J
authors: TJ
authors: Kipps
authors: Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.
authors: Michael D
authors: MD
authors: Burkart
authors: Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA CLL Research Consortium, and Department of Medicine, University of California, San Diego, La Jolla, CA, USA jecastro@ucsd.edu mburkart@ucsd.edu.
authors: Januario E
authors: JE
authors: Castro
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D004852:Epoxy Compounds / Q000494:pharmacology*; D015870:Gene Expression; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D018942:Macrolides / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D010750:Phosphoproteins / Q000235:genetics / Q000378:metabolism; D012326:RNA Splicing / Q000187:drug effects; D000072260:RNA Splicing Factors; D012333:RNA, Messenger / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D017413:Ribonucleoprotein, U2 Small Nuclear / Q000235:genetics / Q000378:metabolism; D017381:Spliceosomes / Q000187:drug effects*; D016019:Survival Analysis; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D004852:Epoxy Compounds; C091810:FD 895; D018942:Macrolides; D010750:Phosphoproteins; D000072260:RNA Splicing Factors; D012333:RNA, Messenger; D017413:Ribonucleoprotein, U2 Small Nuclear; C112491:SF3B1 protein, human; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C522342:pladienolide B